Evergreening Patent Exclusivity in Pharmaceutical Products (ePub)
Supplementary Protection Certificates, Orphan Drugs, Paediatric Extensions and ATMPs
(Sprache: Englisch)
This book analyses 4 central pieces of EU pharmaceutical regulation: the Orphan Drugs Regulation, the Paediatric Regulation, the Supplementary Protection Certificate Regulation, and the ATMP (Advanced Therapy Medicinal Products) Regulation. These four...
sofort als Download lieferbar
eBook (ePub)
Fr. 61.90
inkl. MwSt.
- Kreditkarte, Paypal, Rechnung
- Kostenloser tolino webreader
Produktdetails
Produktinformationen zu „Evergreening Patent Exclusivity in Pharmaceutical Products (ePub)“
This book analyses 4 central pieces of EU pharmaceutical regulation: the Orphan Drugs Regulation, the Paediatric Regulation, the Supplementary Protection Certificate Regulation, and the ATMP (Advanced Therapy Medicinal Products) Regulation. These four regulatory instruments constitute focal points in the pharmaceutical industry's approach to modern business and legal strategy. Their central role is justified by the way these regulatory instruments interact with each other and with the patent system, and by the considerable impact they (as a whole) have for the evergreening of exclusive rights on pharmaceutical products.
The book guides the reader through the latest case law and legislative developments and discusses how these influence strategic legal and business choices in the pharmaceutical industry. It brings to the forefront the often-overlooked significance of the legislative architecture of the EU pharmaceutical regulatory framework, and evaluates its results through the lens of the efficiency test.
The book is an important resource for academics and practitioners interested in updated case law and an in-depth analysis of these four regulations. It is also important for those interested in legislative studies, evaluation of legislation and a critical approach to legislative architecture.
The book guides the reader through the latest case law and legislative developments and discusses how these influence strategic legal and business choices in the pharmaceutical industry. It brings to the forefront the often-overlooked significance of the legislative architecture of the EU pharmaceutical regulatory framework, and evaluates its results through the lens of the efficiency test.
The book is an important resource for academics and practitioners interested in updated case law and an in-depth analysis of these four regulations. It is also important for those interested in legislative studies, evaluation of legislation and a critical approach to legislative architecture.
Autoren-Porträt von Frantzeska Papadopoulou
Frantzeska Papadopoulou is Associate Professor in Intellectual Property Rights and the Head of the IP Group at the Law Faculty of Stockholm University, Sweden. She is one of the founders of the Stockholm IP Law Review and has extensive experience as a practitioner in the field of patent law and regulatory rights.
Bibliographische Angaben
- Autor: Frantzeska Papadopoulou
- 2021, 1. Auflage, 368 Seiten, Englisch
- Verlag: Bloomsbury UK
- ISBN-10: 150995029X
- ISBN-13: 9781509950294
- Erscheinungsdatum: 23.09.2021
Abhängig von Bildschirmgrösse und eingestellter Schriftgrösse kann die Seitenzahl auf Ihrem Lesegerät variieren.
eBook Informationen
- Dateiformat: ePub
- Grösse: 0.39 MB
- Mit Kopierschutz
Sprache:
Englisch
Kopierschutz
Dieses eBook können Sie uneingeschränkt auf allen Geräten der tolino Familie lesen. Zum Lesen auf sonstigen eReadern und am PC benötigen Sie eine Adobe ID.
Kommentar zu "Evergreening Patent Exclusivity in Pharmaceutical Products"
0 Gebrauchte Artikel zu „Evergreening Patent Exclusivity in Pharmaceutical Products“
| Zustand | Preis | Porto | Zahlung | Verkäufer | Rating |
|---|
Schreiben Sie einen Kommentar zu "Evergreening Patent Exclusivity in Pharmaceutical Products".
Kommentar verfassen